Scheduling, administration, biomarkers, and practical guidance.
Anecdotal 'safe default' — not a clinically validated dose. Cycling is a community convention for safety conservatism, not a pharmacologically specific schedule.
Used by some practitioners for acute injury or active disease; no clinical trial data validates loading vs steady-state dosing. Consider conservative default unless specialist guidance directs otherwise.
The Phase IIb dose that showed symptom reduction in celiac. 1 mg and 2 mg doses were no more effective than placebo due to in-lumen peptide cleavage and fragment-driven inhibition. Do not escalate above 0.5 mg TID.
Oral route is plausible mechanistically because KPV enters epithelial cells via PepT1. Subcutaneous administration is also used in some protocols.
Anecdotal advanced dosing; no clinical trial validation for the higher dose.
Observe the 4-week maximum cycle ceiling. LL-37 is immunostimulatory; prolonged use risks immune fatigue and chronic inflammation.
Do not exceed 300 mcg/day — paradoxical GI disruption (nausea, bloating, loose stools) emerges at that ceiling due to antimicrobial impact on commensal flora.
LL-37's cycling requirement is mechanism-driven (immune fatigue); BPC-157 and KPV cycling is conservatism rather than pharmacologically required. Combination protocols should prioritise LL-37's cycle discipline.